REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Numerous extension and long-term observational studies were presented at ACTRIMS/ECTRIMS 2014 for current disease-modifying therapies (DMT). The following is a summary by treatment. Read More

REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Cognitive outcomes appear to be similar in pediatric-onset MS and adult-onset MS despite a longer disease duration in younger patients (Hakiki et al. ECTRIMS 2014; abstract YI2.3).

Neuropsychological performance was assessed with the Rao Brief Repeatable Battery and the Stroop test in 14 patients with a history of pediatric-onset MS and 30 age-matched adult RRMS patients. Duration of MS was 9.8 years and 3.7 years, respectively. Mean EDSS score was 1.7 and 1.5. Mean age for the two groups was 26 years. Read More

REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Testing for oligoclonal Ig bands in cerebrospinal fluid is useful in predicting which patients with clinically isolated syndrome (CIS) are at risk of developing clinically-definite MS (Tumani et al. ECTRIMS 2014; abstract P197). Read More

REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – A U.S. survey of academic and community neurologists from the Consortium of Multiple Sclerosis Centers (CMSC) reports that clinicians tend to favour an earlier, more aggressive treatment approach (Tornatore et al. ECTRIMS 2014; abstract P295). Read More